RU2010137915A - Полипептиды апортинина для транспорта соединения через гематоэнцефалический барьер - Google Patents

Полипептиды апортинина для транспорта соединения через гематоэнцефалический барьер Download PDF

Info

Publication number
RU2010137915A
RU2010137915A RU2010137915/10A RU2010137915A RU2010137915A RU 2010137915 A RU2010137915 A RU 2010137915A RU 2010137915/10 A RU2010137915/10 A RU 2010137915/10A RU 2010137915 A RU2010137915 A RU 2010137915A RU 2010137915 A RU2010137915 A RU 2010137915A
Authority
RU
Russia
Prior art keywords
polypeptide
polypeptide according
specified
patient
conjugate
Prior art date
Application number
RU2010137915/10A
Other languages
English (en)
Other versions
RU2611193C2 (ru
Inventor
Ришар БЕЛИВО (CA)
Ришар БЕЛИВО
Мишель ДЕМЕЛЕ (CA)
Мишель ДЕМЕЛЕ
Кристиан ШЕ (CA)
Кристиан ШЕ
Энтони РЕДЖИНА (CA)
Энтони РЕДЖИНА
Original Assignee
Анджиокем Инк. (Ca)
Анджиокем Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36916132&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2010137915(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Анджиокем Инк. (Ca), Анджиокем Инк. filed Critical Анджиокем Инк. (Ca)
Publication of RU2010137915A publication Critical patent/RU2010137915A/ru
Application granted granted Critical
Publication of RU2611193C2 publication Critical patent/RU2611193C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C07K14/8117—Bovine/basic pancreatic trypsin inhibitor (BPTI, aprotinin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)

Abstract

1. Полипептид, включающий аминокислотную последовательность, имеющую по меньшей мере 80% идентичность аминокислотной последовательности Angiopep-1 (SEQ ID NO:67), где указанный полипептид имеет замену в положении, соответствующем положению 7 цистеина последовательности Angiopep-1, или его фармацевтически приемлемая соль. ! 2. Полипептид по п.1, где указанный полипептид способен преодолевать гематоэнцефалический барьер или его модель in vitro. ! 3. Полипептид по п.1, где указанная процентная идентичность составляет по меньшей мере 85%. ! 4. Полипептид по п.3, где указанная процентная идентичность составляет по меньшей мере 90%. ! 5. Полипептид по п.1, где указанная замена представляет собой замену серином. ! 6. Полипептид по п.5, включающий Angiopep-2 (SEQ ID NO:97). ! 7. Композиция, содержащая полипептид по п.1. ! 8. Фармацевтическая композиция, содержащая полипептид по любому из пп.1-6 и фармацевтически приемлемый носитель. ! 9. Полипептид по любому из пп.1-6, где указанный полипептид представляет собой слитый белок. ! 10. Полипептид по п.9, где указанный слитый белок включает лептин. ! 11. Способ лечения пациента, страдающего ожирением, включающий введение указанному пациенту полипептида по п.10 в эффективном количестве. ! 12. Конъюгат, содержащий: ! (а) полипептид по любому пп.1-6; и ! (b) пептид, белок или низкомолекулярное лекарственное средство, где указанный пептид, белок или низкомолекулярное лекарственное средство конъюгировано с указанным полипептидом. ! 13. Конъюгат по п.12, где указанный белок включает лептин. ! 14. Способ лечения пациента, страдающего ожирением, включающий введение указанному пациенту конъюгата по п.13 в эффективном количестве. ! 15. Конъюгат по п.

Claims (18)

1. Полипептид, включающий аминокислотную последовательность, имеющую по меньшей мере 80% идентичность аминокислотной последовательности Angiopep-1 (SEQ ID NO:67), где указанный полипептид имеет замену в положении, соответствующем положению 7 цистеина последовательности Angiopep-1, или его фармацевтически приемлемая соль.
2. Полипептид по п.1, где указанный полипептид способен преодолевать гематоэнцефалический барьер или его модель in vitro.
3. Полипептид по п.1, где указанная процентная идентичность составляет по меньшей мере 85%.
4. Полипептид по п.3, где указанная процентная идентичность составляет по меньшей мере 90%.
5. Полипептид по п.1, где указанная замена представляет собой замену серином.
6. Полипептид по п.5, включающий Angiopep-2 (SEQ ID NO:97).
7. Композиция, содержащая полипептид по п.1.
8. Фармацевтическая композиция, содержащая полипептид по любому из пп.1-6 и фармацевтически приемлемый носитель.
9. Полипептид по любому из пп.1-6, где указанный полипептид представляет собой слитый белок.
10. Полипептид по п.9, где указанный слитый белок включает лептин.
11. Способ лечения пациента, страдающего ожирением, включающий введение указанному пациенту полипептида по п.10 в эффективном количестве.
12. Конъюгат, содержащий:
(а) полипептид по любому пп.1-6; и
(b) пептид, белок или низкомолекулярное лекарственное средство, где указанный пептид, белок или низкомолекулярное лекарственное средство конъюгировано с указанным полипептидом.
13. Конъюгат по п.12, где указанный белок включает лептин.
14. Способ лечения пациента, страдающего ожирением, включающий введение указанному пациенту конъюгата по п.13 в эффективном количестве.
15. Конъюгат по п.12, где низкомолекулярное лекарственное средство выбрано из группы, состоящей из паклитаксела, винбластина, винкристина, этопозида, доксорубицина, циклофосфамида, таксотера, мелфалана и хлорамбуцила.
16. Способ лечения пациента, страдающего раком мозга, включающий введение указанному пациенту конъюгата по п.15 в эффективном количестве.
17. Способ по п.16, где указанный рак представляет опухоль мозга или метастаз в мозг.
18. Нуклеиновая кислота, кодирующая полипептид по п.1.
RU2010137915A 2005-02-18 2010-09-13 Полипептиды апротинина для транспорта соединения через гематоэнцефалический барьер RU2611193C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65392805P 2005-02-18 2005-02-18
US60/653,928 2005-02-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2007134566/10A Division RU2408605C2 (ru) 2005-02-18 2005-07-21 Полипептид, способный преодолевать гематоэнцефалический барьер, и его конъюгат

Publications (2)

Publication Number Publication Date
RU2010137915A true RU2010137915A (ru) 2012-03-20
RU2611193C2 RU2611193C2 (ru) 2017-02-21

Family

ID=36916132

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2007134566/10A RU2408605C2 (ru) 2005-02-18 2005-07-21 Полипептид, способный преодолевать гематоэнцефалический барьер, и его конъюгат
RU2010137915A RU2611193C2 (ru) 2005-02-18 2010-09-13 Полипептиды апротинина для транспорта соединения через гематоэнцефалический барьер

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2007134566/10A RU2408605C2 (ru) 2005-02-18 2005-07-21 Полипептид, способный преодолевать гематоэнцефалический барьер, и его конъюгат

Country Status (19)

Country Link
US (4) US7902156B2 (ru)
EP (2) EP1859041B2 (ru)
JP (3) JP5175108B2 (ru)
CN (2) CN104311653B (ru)
AT (1) ATE551422T1 (ru)
AU (1) AU2005327497B2 (ru)
BR (1) BRPI0520032A2 (ru)
CA (1) CA2597958C (ru)
CY (1) CY1113299T1 (ru)
DK (2) DK1859041T4 (ru)
ES (2) ES2383901T5 (ru)
HK (1) HK1116363A1 (ru)
MX (1) MX2007010113A (ru)
PL (2) PL1859041T5 (ru)
PT (2) PT2360258E (ru)
RU (2) RU2408605C2 (ru)
SI (2) SI2360258T1 (ru)
WO (1) WO2006086870A1 (ru)
ZA (1) ZA200706917B (ru)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1583562T3 (da) 2003-01-06 2011-09-19 Angiochem Inc Angiopep-1, beslægtede forbindelser og anvendelser deraf
US7485706B2 (en) * 2003-07-30 2009-02-03 The Board Of Trustees Of The Leland Stanford Junior University Neurodegenerative protein aggregation inhibition methods and compounds
US7906625B2 (en) * 2005-01-24 2011-03-15 Amgen Inc. Humanized anti-amyloid antibody
ES2383901T5 (es) * 2005-02-18 2015-02-25 Angiochem Inc. Polipéptidos de aprotinina para transportar un compuesto a través de la barrera sangre-cerebro
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
ES2424242T3 (es) * 2005-07-15 2013-09-30 Angiochem Inc. Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos
EP2074142A4 (en) 2006-10-19 2010-10-27 Angiochem Inc COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
JP5844971B2 (ja) * 2007-05-29 2016-01-20 アンジオケム，インコーポレーテッド コンジュゲートされた物質を組織に送達するためのアプロチニン様ポリペプチド
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
PL2164866T3 (pl) 2007-05-29 2014-10-31 Angiochem Inc Polipeptydy podobne do aprotyniny do dostarczania skoniugowanych z nimi środków do tkanek
CN101946001A (zh) * 2007-12-20 2011-01-12 安吉奥开米公司 多肽-核酸结合物及其应用
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
CA2721169A1 (en) * 2008-04-14 2009-10-22 Proscan Rx Pharma Inc. Prostate specific membrane antigen antibodies and antigen binding fragments
JP5860698B2 (ja) * 2008-04-18 2016-02-16 アンジオケム，インコーポレーテッド パクリタキセル、パクリタキセル類似体またはパクリタキセルコンジュゲートの医薬組成物ならびに関連する調製方法および使用方法
BRPI0920209A2 (pt) 2008-10-15 2015-12-22 Angiochem Inc conjugados de agonistas de glp-1 e usos dos mesmos
RU2531591C2 (ru) * 2008-10-15 2014-10-20 Ангиокем Инк. Конъюгаты этопозида и доксорубицина для доставки лекарственных средств
CN102348723A (zh) * 2008-12-05 2012-02-08 安吉奥开米公司 肽治疗剂轭合物及其应用
CN102272163A (zh) * 2008-12-05 2011-12-07 安吉奥开米公司 瘦素和瘦素类似物结合物及其用途
US9914754B2 (en) 2008-12-05 2018-03-13 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
MX2011006685A (es) 2008-12-17 2011-09-27 Angiochem Inc Inhibidores de metaloproteinas de matriz de membrana tipo-1 y sus usos.
ES2729261T3 (es) * 2009-04-20 2019-10-31 Angiochem Inc Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2
US20100284921A1 (en) * 2009-05-08 2010-11-11 Temple University - Of The Commonwealth System Of Higher Education Targeted nanoparticles for intracellular cancer therapy
CA2764777A1 (en) * 2009-06-11 2010-12-16 Angiochem Inc. Fusion proteins for delivery of gdnf and bdnf to the central nervous system
IN2012DN00248A (ru) 2009-07-02 2015-05-01 Angiochem Inc
JP2013506697A (ja) * 2009-10-06 2013-02-28 アンジオケム インコーポレーテッド 治療薬を輸送するための組成物と方法
NO2719708T3 (ru) 2009-11-13 2018-03-24
CA2803646A1 (en) 2010-07-02 2012-01-05 Angiochem Inc. Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
US20130280281A1 (en) * 2010-07-02 2013-10-24 Jean-Paul Castaigne Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
EP2601220A2 (en) 2010-08-06 2013-06-12 U3 Pharma GmbH Use of her3 binding agents in prostate treatment
CN102614524A (zh) * 2011-02-01 2012-08-01 复旦大学 低密度脂蛋白受体相关蛋白配体多肽修饰的脑肿瘤靶向基因递释复合物
WO2013056096A1 (en) * 2011-10-13 2013-04-18 Angiochem Inc. Polypeptide-opioid conjugates and uses thereof
EP2885318A4 (en) 2012-08-14 2016-03-30 Angiochem Inc PEPTIDE-DENDRIMER CONJUGATES AND USES THEREOF
JP6108265B2 (ja) * 2012-11-19 2017-04-05 国立大学法人 千葉大学 脳送達用キャリアおよびその用途
AU2014312190A1 (en) 2013-08-28 2016-02-18 Bioasis Technologies Inc. CNS-targeted conjugates of antibodies
EP3107928B1 (en) * 2014-02-19 2019-09-04 F. Hoffmann-La Roche AG Blood brain barrier shuttle
US11318206B2 (en) 2014-03-28 2022-05-03 Aposense Ltd Compounds and methods for trans-membrane delivery of molecules
WO2015145417A1 (en) * 2014-03-28 2015-10-01 Ilan Ziv Compounds and methods for trans-membrane delivery of molecules
US9993563B2 (en) * 2014-03-28 2018-06-12 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
US11241520B2 (en) 2014-08-07 2022-02-08 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US9655998B2 (en) 2014-08-07 2017-05-23 Cook Medical Technologies Llc Encapsulated drug compositions and methods of use thereof
US9180226B1 (en) 2014-08-07 2015-11-10 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US10370432B2 (en) 2014-10-03 2019-08-06 University Of Massachusetts Heterologous targeting peptide grafted AAVS
US10711270B2 (en) 2014-10-03 2020-07-14 University Of Massachusetts High efficiency library-identified AAV vectors
EP3222291B1 (en) * 2014-10-24 2020-08-19 University of Science and Technology of China Angiopeptin conjugates for amyloid protein targeting
JP6474893B2 (ja) * 2014-11-06 2019-02-27 オーエスイー・イミュノセラピューティクス 脳転移の処置のための治療用マルチペプチドｔ特異的免疫療法
WO2016131009A1 (en) 2015-02-13 2016-08-18 University Of Massachusetts Compositions and methods for transient delivery of nucleases
JP6612063B2 (ja) * 2015-06-11 2019-11-27 国立大学法人滋賀医科大学 悪性神経膠腫分子標的ペプチド
ES2826827T3 (es) * 2015-06-15 2021-05-19 Angiochem Inc Métodos para el tratamiento de carcinomatosis leptomeníngea
PL417159A1 (pl) 2016-05-11 2017-11-20 Instytut Biologii Doświadczalnej Im. Marcelego Nenckiego Koniugaty białka prionowego z dendrymerami do zastosowania w leczeniu choroby Alzheimera
CN110267674A (zh) * 2016-07-08 2019-09-20 奥美药业有限公司 包含瘦素的融合蛋白及其生产和使用方法
US10702589B2 (en) 2016-10-04 2020-07-07 Ann And Robert H. Lurie Children's Hospital Of Chicago Compositions and methods of treating neurological disorder and stress-induced conditions
WO2018127927A1 (en) 2017-01-09 2018-07-12 Aposense Ltd. Compounds and methods for trans-membrane delivery of molecules
US10688191B2 (en) 2018-01-19 2020-06-23 Hr Biomed, Llc Delivery of a chemotherapy agent across the blood-brain barrier
CN109666973B (zh) * 2018-11-21 2022-11-04 北京大学 一种穿过血脑屏障的肽库及其筛选方法
CA3128035A1 (en) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Combination therapies for delivery across the blood brain barrier
WO2022156531A1 (zh) * 2021-01-19 2022-07-28 中国人民解放军军事科学院军事医学研究院 一种能够透过生物屏障的动力蛋白结合肽及其应用
CN112851789B (zh) * 2021-02-04 2022-10-18 大理大学 一种脑靶向hiv进入抑制剂多肽及其应用
AU2022222778A1 (en) * 2021-02-22 2023-08-31 Yale University Targeted bifunctional degraders and methods using same

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
ZA871844B (en) 1986-03-13 1988-05-25 Biotechnology Pty Ltd Method of assay of inhibin
GB2188322A (en) * 1986-03-26 1987-09-30 Bayer Ag Aprotinin and analogues thereof produced by a recombinant host
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4904768A (en) * 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
GB2208511A (en) * 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
US5258499A (en) * 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US5028697A (en) * 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5169933A (en) * 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5948634A (en) * 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
DE3912638A1 (de) 1989-04-18 1990-10-31 Bayer Ag Gentechnologisch hergestellte homologe des alzheimer protease inhibitors, wirtstaemme sowie expressionsvektoren fuer ihre herstellung und ihre verwendung als arzneimittel
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US6475781B1 (en) * 1990-05-17 2002-11-05 Dana-Farber Cancer Institute, Inc. Trans-dominant suppressor genes for oligomeric proteins
US5714167A (en) * 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US6495513B1 (en) * 1991-03-11 2002-12-17 Curis, Inc. Morphogen-enhanced survival and repair of neural cells
US5955444A (en) * 1991-08-09 1999-09-21 Massachusetts Institute Of Technology Method of inhibiting abnormal tau hyper phosphorylation in a cell
US5627270A (en) * 1991-12-13 1997-05-06 Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
EP0671944A4 (en) 1992-09-25 1996-07-24 Corvas Int Inc TISSUE VIA-THROMBOPLASTIN FACTOR COMPLEX INHIBITORS DERIVED FROM A BOVINE PANCREATIC TRYPSIN INHIBITOR.
WO1994019692A1 (en) * 1993-02-18 1994-09-01 The General Hospital Corporation Alzheimer's disease therapeutics
WO1996031531A2 (en) 1995-04-04 1996-10-10 Advanced Bioconcept, Inc. Fluorescent peptides
ZA963619B (en) * 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
WO1996035788A2 (en) 1995-05-08 1996-11-14 Scios, Inc. Kunitz type protease inhibitors
AU5908296A (en) 1995-05-31 1996-12-24 Fred Hutchinson Cancer Research Center Compositions and methods for targeted delivery of effector m olecules
US5780265A (en) 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
IL126115A (en) * 1996-03-11 2007-03-08 Aerovance Inc Significantly purified protein with suppressive activity for sirin protease and its pharmaceutical preparations
JP2000509394A (ja) 1996-05-01 2000-07-25 アンティバイラルズ インコーポレイテッド 細胞膜を横切って物質を輸送するためのポリペプチド結合体
DE19629982A1 (de) * 1996-07-25 1998-01-29 Bayer Ag Aprotinin-Varianten mit verbesserten Eigenschaften
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
EP0932390A1 (en) * 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
AU6682598A (en) 1997-03-04 1998-09-22 Bio-Technology General Corporation Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
BR9809138A (pt) * 1997-05-21 2001-08-28 Trustees For The Leland Stanfo Conjugado e método para aumentar o transporte de um composto selecionado atravessando uma membrana biológica
US6093692A (en) * 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US6475481B2 (en) * 1997-11-18 2002-11-05 Canji Inc Purging of stem cell products
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US5981564A (en) * 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
WO2000050059A1 (en) * 1999-02-24 2000-08-31 The Uab Research Foundation Taxane derivatives for targeted therapy of cancer
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
US6180607B1 (en) * 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
DE19953696A1 (de) 1999-11-09 2001-05-10 Alexander Cherkasky Selektive proteolytische Synzyme (SPS)
CA2355334A1 (en) 2000-10-16 2002-04-16 Procyon Biopharma Inc. Pharmaceutical preparations and methods for inhibiting tumors
AU2002254400B2 (en) * 2001-03-23 2007-08-09 Napro Biotherapeutics, Inc. Molecular conjugates for use in treatment of cancer
EP2147679B1 (en) * 2001-07-25 2014-06-25 Raptor Pharmaceutical, Inc. Compositions for blood-brain barrier transport
CN1195845C (zh) * 2001-10-08 2005-04-06 中国医学科学院阜外心血管病医院 人源抑肽酶基因、该基因编码的蛋白质及其应用
US7192921B2 (en) * 2001-11-08 2007-03-20 The Burnham Institute Peptides that home to tumor lymphatic vasculature and methods of using same
CA2474283A1 (en) * 2002-02-07 2003-08-14 Yissum Research Development Company Of The Hebrew University In Jerusale M Amino acid sequences capable of facilitating penetration across a biological barrier
US20050215478A1 (en) * 2002-02-07 2005-09-29 Ben-Sasson Shmuel A Amino acid sequences capable of facilitating penetration across a biological barrier
EP1539208A2 (en) * 2002-06-28 2005-06-15 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
US7829694B2 (en) * 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
DK1583562T3 (da) * 2003-01-06 2011-09-19 Angiochem Inc Angiopep-1, beslægtede forbindelser og anvendelser deraf
WO2004108071A2 (en) * 2003-06-05 2004-12-16 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
CA2525236C (en) 2003-06-20 2015-03-24 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7927811B2 (en) * 2003-08-08 2011-04-19 Proteus Sciences Co., Ltd. Polypeptides having brain-localizing activity and uses thereof
US20050058702A1 (en) * 2003-09-17 2005-03-17 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
US7208174B2 (en) * 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
WO2006039253A2 (en) * 2004-09-29 2006-04-13 Children's Memorial Hospital Sirna-mediated gene silencing of alpha synuclein
ES2383901T5 (es) * 2005-02-18 2015-02-25 Angiochem Inc. Polipéptidos de aprotinina para transportar un compuesto a través de la barrera sangre-cerebro
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
EP1888121A2 (en) * 2005-05-12 2008-02-20 Tapestry Pharmaceuticals, Inc. Anticancer targeted conjugates comprising a succinyl or glutaryl linker
ES2424242T3 (es) * 2005-07-15 2013-09-30 Angiochem Inc. Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos
GB0517092D0 (en) 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
AU2006287481A1 (en) 2005-09-08 2007-03-15 Mdrna, Inc. Pharmaceutical compositions for delivery of ribonucleic acid to a cell
EP2202239A1 (en) * 2005-11-01 2010-06-30 Alnylam Pharmaceuticals Inc. RNAI inhibition of influenza virus replication
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
CN101511868B (zh) 2006-07-24 2013-03-06 比奥雷克西斯制药公司 毒蜥外泌肽融合蛋白
EP2074142A4 (en) 2006-10-19 2010-10-27 Angiochem Inc COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
PL2164866T3 (pl) 2007-05-29 2014-10-31 Angiochem Inc Polipeptydy podobne do aprotyniny do dostarczania skoniugowanych z nimi środków do tkanek
WO2009039188A1 (en) 2007-09-17 2009-03-26 Ludwig Institute For Cancer Research Ltd Peptides and methods for the treatment of gliomas and other cancers
WO2009070597A2 (en) 2007-11-26 2009-06-04 Armagen Technologies, Inc. Fusion proteins for delivery of gdnf to the cns
CN101946001A (zh) 2007-12-20 2011-01-12 安吉奥开米公司 多肽-核酸结合物及其应用
JP5860698B2 (ja) 2008-04-18 2016-02-16 アンジオケム，インコーポレーテッド パクリタキセル、パクリタキセル類似体またはパクリタキセルコンジュゲートの医薬組成物ならびに関連する調製方法および使用方法
BRPI0920209A2 (pt) 2008-10-15 2015-12-22 Angiochem Inc conjugados de agonistas de glp-1 e usos dos mesmos
RU2531591C2 (ru) 2008-10-15 2014-10-20 Ангиокем Инк. Конъюгаты этопозида и доксорубицина для доставки лекарственных средств
CN102348723A (zh) 2008-12-05 2012-02-08 安吉奥开米公司 肽治疗剂轭合物及其应用
CN102272163A (zh) 2008-12-05 2011-12-07 安吉奥开米公司 瘦素和瘦素类似物结合物及其用途
US9914754B2 (en) * 2008-12-05 2018-03-13 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
MX2011006685A (es) 2008-12-17 2011-09-27 Angiochem Inc Inhibidores de metaloproteinas de matriz de membrana tipo-1 y sus usos.

Also Published As

Publication number Publication date
ATE551422T1 (de) 2012-04-15
DK2360258T3 (en) 2015-01-12
SI1859041T2 (sl) 2015-04-30
JP5175108B2 (ja) 2013-04-03
US20060189515A1 (en) 2006-08-24
PL1859041T3 (pl) 2012-10-31
EP1859041B1 (en) 2012-03-28
JP2011144174A (ja) 2011-07-28
ZA200706917B (en) 2008-10-29
EP1859041A4 (en) 2008-10-08
ES2527634T3 (es) 2015-01-27
DK1859041T4 (en) 2015-02-09
HK1116363A1 (en) 2008-12-19
SI1859041T1 (sl) 2012-07-31
WO2006086870A1 (en) 2006-08-24
PT1859041E (pt) 2012-06-19
CN104311653B (zh) 2017-12-05
JP5462193B2 (ja) 2014-04-02
US7557182B2 (en) 2009-07-07
CA2597958A1 (en) 2006-08-24
ES2383901T5 (es) 2015-02-25
CN101160403A (zh) 2008-04-09
EP2360258A2 (en) 2011-08-24
ES2383901T3 (es) 2012-06-27
EP2360258A3 (en) 2011-12-14
RU2611193C2 (ru) 2017-02-21
JP2008529539A (ja) 2008-08-07
CY1113299T1 (el) 2016-04-13
DK1859041T3 (da) 2012-07-02
RU2007134566A (ru) 2009-03-27
US7902156B2 (en) 2011-03-08
SI2360258T1 (sl) 2015-02-27
PL1859041T5 (pl) 2015-05-29
CA2597958C (en) 2019-01-15
MX2007010113A (es) 2007-12-07
PT2360258E (pt) 2015-01-13
CN104311653A (zh) 2015-01-28
AU2005327497A1 (en) 2006-08-24
CN101160403B (zh) 2014-08-13
US20150174266A1 (en) 2015-06-25
EP1859041B2 (en) 2014-11-19
RU2408605C2 (ru) 2011-01-10
JP2014088386A (ja) 2014-05-15
US8828949B2 (en) 2014-09-09
EP2360258B1 (en) 2014-10-08
BRPI0520032A2 (pt) 2009-04-14
US20110171128A1 (en) 2011-07-14
EP1859041A1 (en) 2007-11-28
US20080299039A1 (en) 2008-12-04
PL2360258T3 (pl) 2015-03-31
AU2005327497B2 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
RU2010137915A (ru) Полипептиды апортинина для транспорта соединения через гематоэнцефалический барьер
JP6223377B2 (ja) 長期間作用性ペプチド類似体のための組成物
JP2009500431A5 (ru)
RU2008105677A (ru) Усиление действия противораковых агентов
US20220048961A1 (en) Transferrin receptor targeting peptides
JP2016521257A (ja) ヘプシジン類似体及びその使用
IL223678A (en) Immunosuppressive Modulation Compounds
US20230106131A1 (en) Polypeptide conjugates for intracellular delivery of stapled peptides
CA2880342A1 (en) Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
WO2011094671A2 (en) N-terminally conjugated polypeptides for targeted therapy and diagnosis
JP2016523825A (ja) 腎毒性活性物質からの保護のための接合体
KR101956302B1 (ko) 세포 내부 pH 감응성 융합 펩티드 및 이를 유효성분으로 포함하는 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환을 예방 또는 치료하기 위한 약학 조성물
US10005826B2 (en) Compounds that bind to the erythropoietin receptor
JP7357292B2 (ja) 癌治療用ペプチド
WO2023150618A2 (en) Conjugated hepcidin mimetics
Huang Biomimicry: Exploring Peptoids and Recombinant Protein Polymers for Biomedical Applications